Dose Insider / FDA warning letters / NuScience Peptides LLC

NuScience Peptides LLCFDA warning letter, August 24, 2026

FDA letter of August 24, 2026 · posted September 1, 2026 · checked against fda.gov on November 20, 2026

On August 24, 2026, FDA sent NuScience Peptides LLC of Cornelius, NC, a warning letter saying that nusciencepeptides.com offered semaglutide, retatrutide, survodutide and mazdutide that FDA considers unapproved new drugs.

2 sectionsof the Food, Drug, and Cosmetic Act cited in the letter
FDA letters on GLP-1 drugs, by yearAll 164 letters in this database; the year of this one in coral202322024112025732026, this letter78FDA letters on GLP-1 drugs,by yearAll 164 letters in this database; the year of thisone in coral202322024112025732026, this letter78

16 letters are of the same kind as this one: other matters, such as a clinical investigator or a supplement.

On this page

FDA posted the letter on September 1, 2026. As of November 20, 2026, FDA’s database lists no close-out letter for it. It is one of 164 FDA warning letters about GLP-1 drugs in this database, which we built from FDA’s own records.1

What does the letter say, in brief?

CompanyNuScience Peptides LLC
LocationCornelius, NC
Website namednusciencepeptides.com, pubchem.ncbi.nlm.nih.gov
Letter datedAugust 24, 2026
Posted by FDASeptember 1, 2026
Issuing officeCenter for Drug Evaluation and Research (CDER)
FDA’s subject lineUnapproved New Drugs/Misbranded
Drugs namedsemaglutide, retatrutide, survodutide and mazdutide
Kind of letterOther
Reply asked withinNo number of days stated
Close-out letterNone posted as of November 20, 2026
FDA recordMARCS-CMS 733652

What did FDA quote?

The letter quotes 12 passages. FDA quotes them as examples and says in most letters that the list is not exhaustive.1

4 more quotes are in the full letter below.

Which parts of the law did FDA cite?

The letter cites 2 sections of the Federal Food, Drug, and Cosmetic Act. The right-hand column shows how many of the 164 letters in this database cite the same section.

SectionWhat it saysLetters citing it
505(a)A new drug may not be sold across state lines without an approved application48
301(d)It is prohibited to introduce a drug into interstate commerce in violation of section 50548

What did FDA ask the company to do?

FDA has not posted a reply or a close-out letter for this case. A reply sent to FDA is not always published.1

Has FDA warned the seller I use?

Type a seller’s name or website. The search runs over all 164 letters in this database.

Seller check164 letters
Letters found—
Latest—

How many GLP-1 letters has FDA sent?

16 letters in this database are of the same kind as this one, other matters, such as a clinical investigator or a supplement. 151 of the 164 letters name semaglutide. 21 of the 164 letters name retatrutide. 2 of the 164 letters name survodutide. 4 of the 164 letters name mazdutide. The chart counts letters by the quarter of their date; the quarter of this letter is marked.

Letters by quarter2023–2026
Drug named in the letter
Kind of letter
Letters—
Busiest quarter—

Which other sellers got a similar letter?

What does an FDA warning letter mean for someone buying from this seller?

FDA sends a warning letter when it finds what it believes are significant violations of federal law. The letter names the concerns, such as how a drug was made or what a seller claimed about it, and asks for a reply within a set time.2 A letter is not a court ruling and not a recall. The company can correct the problems or send FDA its reasons for disagreeing.

FDA itself warns that what happened after a letter may have changed the regulatory status of the issues in it.3 When the issuing office has checked that the corrections are adequate, it can issue a close-out letter; if the violations are seen again, FDA can take enforcement action without further notice.2 So the date matters: a letter from 2024 says what FDA found then, not what the seller does today.

A seller with no letter is not a seller FDA has approved. FDA does not approve compounded drugs or the websites that sell them, and most sellers have never been reviewed in a letter at all.

What is the full text of the letter?

This is the letter as FDA published it on fda.gov, without the page navigation. Letters from the U.S. government are in the public domain.1

Read the full letter (1503 words)

Reference Number: 733652

To Joseph and Ratsamy DeRosa:

This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) review of your website. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.

These products are especially concerning from a public health perspective because injectable drug products can pose risks of serious harm to users. Injectable products are delivered directly into the body, sometimes directly into the bloodstream, and therefore, bypass some of the body’s key defenses against toxins and microorganisms that can lead to serious and life-threatening conditions.

FDA Review

Violations were identified and documented during a review of your website nusciencepeptides.com in July 2026. Based on our review, “GLP-2 Tirz Peptide,” “GLP-1 Sema Research Peptide,” “GLP-3 RT (Retatrutide) Research Peptide,” “Survodutide,” “Mazdutide,” “PT-141 Peptide (Bremelanotide),” “Tesamorelin Research Peptide,” “Tesamorelin Ipamorelin Blend,” and “Bacteriostatic water for Peptides (BAC Water)” are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).

This review was conducted as part of FDA’s public health responsibility to protect the public from unsafe, ineffective, and poor-quality drugs.

Violations of the Federal Food, Drug, and Cosmetic Act

The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.

Unapproved New Drug Violations

Based on a review of your website, “GLP-2 Tirz Peptide,” “GLP-1 Sema Research Peptide,” “GLP-3 RT (Retatrutide) Research Peptide,” “Survodutide,” “Mazdutide,” “PT-141 Peptide (Bremelanotide),” “Tesamorelin Research Peptide,” “Tesamorelin Ipamorelin Blend,” and “Bacteriostatic water for Peptides (BAC Water)” are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and/or intended to affect the structure or any function of the body. 1 Examples from your product labeling, including on your website, that provide evidence of the intended use (as defined in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following:

GLP-2 Tirz Peptide

On the webpage https://nusciencepeptides.com/product/glp-2-tz-2/:

“GLP-2 Tirz, a research peptide of significant interest, is known for its dual agonist activity on glucagon-like peptide-2 (GLP-2) and glucose-dependent insulinotropic polypeptide (GIP) receptors. This peptide has been extensively studied in rodent models, particularly rats, to explore its metabolic effects and potential therapeutic applications in various conditions. Researchers use these models to gain valuable insights into the complex mechanisms of metabolic regulation and the integrated actions of incretin hormones.”

GLP-1 Sema Research Peptide

On the webpage https://pubchem.ncbi.nlm.nih.gov/compound/56843331#datasheet=LCSS (hyperlinked from https://nusciencepeptides.com/product/glp-1-sm/):

“**Mechanism of cardiovascular benefit and weight loss** In hypercholesterolemia, semaglutide is believed to reduce the progression of atherosclerosis via decreased gut permeability and decreased inflammation. Weight loss is believed to occur via the reduction of appetite and food cravings after semaglutide administration.”

GLP-3 RT (Retatrutide) Research Peptide

On the webpage https://nusciencepeptides.com/product/glp-3-rt/:

“GLP-3 RT (Retatrutide) is a novel investigational peptide being explored for its potential research applications in metabolic disorders, particularly obesity and type 2 diabetes. Also known as LY3437943, it functions as a triple receptor agonist — a glp3 peptide that targets the GLP-1, GIP, and glucagon receptor pathways simultaneously”

Survodutide

On the webpage https://nusciencepeptides.com/product/survodutide/:

“Survodutide (BI 456906) is a dual agonist targeting both the glucagon receptor (GCGR) and the glucagon-like peptide-1 receptor (GLP-1R), developed for laboratory research into obesity and type 2 diabetes metabolic pathways. Preclinical studies in rodent models have demonstrated its efficacy in promoting weight loss and improving glycemic control.”

“In conclusion, survodutide’s dual GCGR/GLP-1R agonism offers a multifaceted approach to treating metabolic disorders. Its efficacy in preclinical models supports further investigation and development as a subject of investigation for obesity and metabolic disorder research.”

Mazdutide

On the webpage https://nusciencepeptides.com/product/mazdutide/:

“Mazdutide (IBI362), a dual agonist targeting both GLP-1 and glucagon receptors, has shown promising results in clinical trials for weight management and metabolic disorders. This mazdutide peptide has been extensively studied in humans, but preclinical research, particularly in rat models, remains limited.”

“Furthermore, mazdutide has been associated with reductions in liver fat content and improvements in insulin sensitivity in clinical trials, highlighting its potential for treating non-alcoholic fatty liver disease and type 2 diabetes.”

PT-141 Peptide (Bremelanotide)

On the webpage https://nusciencepeptides.com/product/pt-141-bremelanotide/:

“PT-141, also known as bremelanotide, is a synthetic PT-141 peptide classified as a non-selective agonist of melanocortin receptors, with primary activity at MC3R and MC4R. This research peptide has been widely examined in preclinical models to better understand melanocortin-mediated signaling pathways involved in sexual behavior and neuroendocrine regulation.”

“Additional studies examining melanocortin receptor agonists support the role of PT-141 in modulating sexual behaviors across sexes through central nervous system pathways. The involvement of the melanocortin system highlights the relevance of PT-141 peptide in experimental research exploring neural control of sexual function.”

Tesamorelin Research Peptide and Tesamorelin Ipamorelin Blend

On the webpage https://nusciencepeptides.com/product/tesamorelin/:

“Beyond metabolic effects, tesamorelin has demonstrated the ability to reduce muscle fat and increase muscle area in clinical studies . . . [s]uch findings are particularly relevant for exploring interventions in muscle-wasting conditions.”

“Furthermore, research indicates that tesamorelin may enhance cognitive function, including improvements in executive function and verbal memory.”

On the webpage https://nusciencepeptides.com/product/tesamorelin-ipamorelin/:

“Tesamorelin, a growth hormone-releasing hormone (GHRH) analog, has been shown to significantly reduce visceral adipose tissue and improve liver health by decreasing liver fat and preventing fibrosis progression.”

“[R]esearch has indicated that ipamorelin can counteract glucocorticoid-induced reductions in bone formation, suggesting its potential in mitigating bone density loss associated with glucocorticoid therapy.”

Bacteriostatic water for Peptides (BAC Water)

Your firm offers “Bacteriostatic water for Peptides (BAC Water)” for sale to be used to reconstitute the peptide products sold on your website, which are drugs intended for injection, including the above-mentioned products. The sale of these products together demonstrates that you intend for your “Bacteriostatic water for Peptides (BAC Water)” to be used in combination for injection. Therefore, your “Bacteriostatic water for Peptides (BAC Water)” is a drug.

“GLP-2 Tirz Peptide,” “GLP-1 Sema Research Peptide,” “GLP-3 RT (Retatrutide) Research Peptide,” “Survodutide,” “Mazdutide,” “PT-141 Peptide (Bremelanotide),” “Tesamorelin Research Peptide,” “Tesamorelin Ipamorelin Blend,” and “Bacteriostatic water for Peptides (BAC Water)” are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in their labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, these products are unapproved new drugs. The introduction or delivery for introduction into interstate commerce of these unapproved new drug products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).

Conclusion

As previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.

Send your written response to FDAAdvisory@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. Identify your response with reference number “733652” in the subject line of the email.

If you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration.

Please note FDA posts warning letters on www.fda.gov.

Sincerely,

/S/

Tina Smith, M.S.

Captain, U.S. Public Health Service

Director

Office of Unapproved Drugs and Labeling Compliance

Office of Compliance

Center for Drug Evaluation and Research

U.S. Food and Drug Administration

__________________________

1 Despite statements on your product labeling marketing your products “for laboratory, research, and analytical use” and “not intended for human or veterinary use,” evidence obtained from your website establishes that your products are intended to be drugs for human use. In addition to the cited drug claims, you market bacteriostatic water alongside a “peptide calculator,” a resource that provides the means to prepare an injectable drug for human administration.

Content current as of:

09/01/2026

Regulated Product(s)

Drugs

Sources

  1. FDA. Warning letter to NuScience Peptides LLC, August 24, 2026 (MARCS-CMS 733652). fda.gov
  2. FDA. About warning and close-out letters. Content current as of March 20, 2024. fda.gov
  3. FDA. Warning letters: search page and notice on later changes in regulatory status. fda.gov
  4. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. sections 331, 351, 352, 353a, 353b and 355. Office of the Law Revision Counsel. uscode.house.gov

Log every dose in mg with the vial it came from, so there is a record if something goes wrong.

Open Dose Insider